327 related articles for article (PubMed ID: 28042336)
1. Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.
Hultqvist G; Syvänen S; Fang XT; Lannfelt L; Sehlin D
Theranostics; 2017; 7(2):308-318. PubMed ID: 28042336
[TBL] [Abstract][Full Text] [Related]
2. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging.
Syvänen S; Fang XT; Hultqvist G; Meier SR; Lannfelt L; Sehlin D
Neuroimage; 2017 Mar; 148():55-63. PubMed ID: 28069541
[TBL] [Abstract][Full Text] [Related]
3. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain.
Fang XT; Hultqvist G; Meier SR; Antoni G; Sehlin D; Syvänen S
Neuroimage; 2019 Jan; 184():881-888. PubMed ID: 30300753
[TBL] [Abstract][Full Text] [Related]
4. Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.
Syvänen S; Hultqvist G; Gustavsson T; Gumucio A; Laudon H; Söderberg L; Ingelsson M; Lannfelt L; Sehlin D
Alzheimers Res Ther; 2018 May; 10(1):49. PubMed ID: 29793530
[TBL] [Abstract][Full Text] [Related]
5. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.
Niewoehner J; Bohrmann B; Collin L; Urich E; Sade H; Maier P; Rueger P; Stracke JO; Lau W; Tissot AC; Loetscher H; Ghosh A; Freskgård PO
Neuron; 2014 Jan; 81(1):49-60. PubMed ID: 24411731
[TBL] [Abstract][Full Text] [Related]
6. Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease.
Chang R; Knox J; Chang J; Derbedrossian A; Vasilevko V; Cribbs D; Boado RJ; Pardridge WM; Sumbria RK
Mol Pharm; 2017 Jul; 14(7):2340-2349. PubMed ID: 28514851
[TBL] [Abstract][Full Text] [Related]
7. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
[TBL] [Abstract][Full Text] [Related]
8. Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology.
Bourassa P; Alata W; Tremblay C; Paris-Robidas S; Calon F
Mol Pharm; 2019 Feb; 16(2):583-594. PubMed ID: 30609376
[TBL] [Abstract][Full Text] [Related]
9. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
Boado RJ; Zhang Y; Wang Y; Pardridge WM
Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-β.
Sehlin D; Fang XT; Meier SR; Jansson M; Syvänen S
Sci Rep; 2017 Dec; 7(1):17254. PubMed ID: 29222502
[TBL] [Abstract][Full Text] [Related]
11. Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
Zhou QH; Fu A; Boado RJ; Hui EK; Lu JZ; Pardridge WM
Mol Pharm; 2011 Feb; 8(1):280-5. PubMed ID: 21141969
[TBL] [Abstract][Full Text] [Related]
12. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.
Manich G; Cabezón I; del Valle J; Duran-Vilaregut J; Camins A; Pallàs M; Pelegrí C; Vilaplana J
Eur J Pharm Sci; 2013 Jul; 49(4):556-64. PubMed ID: 23748097
[TBL] [Abstract][Full Text] [Related]
13. Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle.
Sehlin D; Stocki P; Gustavsson T; Hultqvist G; Walsh FS; Rutkowski JL; Syvänen S
FASEB J; 2020 Oct; 34(10):13272-13283. PubMed ID: 32779267
[TBL] [Abstract][Full Text] [Related]
14. Age, dose, and binding to TfR on blood cells influence brain delivery of a TfR-transported antibody.
Faresjö R; Sehlin D; Syvänen S
Fluids Barriers CNS; 2023 May; 20(1):34. PubMed ID: 37170266
[TBL] [Abstract][Full Text] [Related]
15. Reducing neonatal Fc receptor binding enhances clearance and brain-to-blood ratio of TfR-delivered bispecific amyloid-β antibody.
Schlein E; Andersson KG; Dallas T; Syvänen S; Sehlin D
MAbs; 2024; 16(1):2339337. PubMed ID: 38634473
[TBL] [Abstract][Full Text] [Related]
16. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
17. A single-chain fragment constant design enables easy production of a monovalent blood-brain barrier transporter and provides an improved brain uptake at elevated doses.
Morrison JI; Metzendorf NG; Rofo F; Petrovic A; Hultqvist G
J Neurochem; 2023 May; 165(3):413-425. PubMed ID: 36681883
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.
Yu YJ; Atwal JK; Zhang Y; Tong RK; Wildsmith KR; Tan C; Bien-Ly N; Hersom M; Maloney JA; Meilandt WJ; Bumbaca D; Gadkar K; Hoyte K; Luk W; Lu Y; Ernst JA; Scearce-Levie K; Couch JA; Dennis MS; Watts RJ
Sci Transl Med; 2014 Nov; 6(261):261ra154. PubMed ID: 25378646
[TBL] [Abstract][Full Text] [Related]
19. Lack of Widespread BBB Disruption in Alzheimer's Disease Models: Focus on Therapeutic Antibodies.
Bien-Ly N; Boswell CA; Jeet S; Beach TG; Hoyte K; Luk W; Shihadeh V; Ulufatu S; Foreman O; Lu Y; DeVoss J; van der Brug M; Watts RJ
Neuron; 2015 Oct; 88(2):289-97. PubMed ID: 26494278
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer's disease.
Gustavsson T; Metzendorf NG; Wik E; Roshanbin S; Julku U; Chourlia A; Nilsson P; Andersson KG; Laudon H; Hultqvist G; Syvänen S; Sehlin D
Alzheimers Res Ther; 2023 May; 15(1):90. PubMed ID: 37131196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
